KY4.F Kyowa Kirin Co. Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
14.50 EUR
Close of Nov 13, 2026
11.53 15.47
Market cap
EUR 7.59B
P/E
16.9x
P/B
1.42x
ROE
-
Dividend yield
2.82%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is KY4.F undervalued?

Graham number
Price14.50
Graham value14.07
Premium3.1%

KY4.F trades 3.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kyowa Kirin Co. Ltd fundamental analysis

No fundamental analysis for Kyowa Kirin Co. Ltd yet.

Kyowa Kirin Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kyowa Kirin Co. Ltd

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for th…

Full company profile